Stockscreener 앱 받기
1.68
5.08%
-0.09
전일 마감가:
$1.77
열려 있는:
$1.72
하루 거래량:
211.02K
Relative Volume:
0.09
시가총액:
$18.82M
수익:
$23.28M
순이익/손실:
$-23.75M
주가수익비율:
-0.5508
EPS:
-3.05
순현금흐름:
$-25.22M
1주 성능:
-8.20%
1개월 성능:
-4.00%
6개월 성능:
-45.81%
1년 성능:
-66.99%
1일 변동 폭
$1.6545
$1.78
1주일 범위
$1.6545
$1.92
52주 변동 폭
$1.25
$6.00
Lifeward Ltd Stock (LFWD) Company Profile
명칭
Lifeward Ltd
전화
15082511154
주소
200 DONALD LYNCH BLVD., MARLBOROUGH
LFWD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFWD
Lifeward Ltd
|
1.68 | 18.82M | 23.28M | -23.75M | -25.22M | -3.05 |
|
ABT
Abbott Laboratories
|
131.54 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.99 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
376.10 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.56 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.75 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Lifeward Ltd Stock (LFWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 개시 | Laidlaw | Buy |
| 2017-04-03 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2016-12-16 | 개시 | Oppenheimer | Outperform |
| 2016-07-15 | 개시 | Piper Jaffray | Overweight |
| 2015-05-22 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2015-05-08 | 재확인 | Barclays | Equal Weight |
| 2014-10-07 | 개시 | Barclays | Equal Weight |
모두보기
Lifeward Ltd 주식(LFWD)의 최신 뉴스
Lifeward Ltd. (LFWD): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton - TradingView
Lifeward gains FDA clearance for new ReWalk exoskeleton - Investing.com
Sector Update: Health Care Stocks Softer Thursday Afternoon -March 13, 2025 at 02:06 pm EDT - Marketscreener.com
Sector Update: Health Care -March 13, 2025 at 01:43 pm EDT - Marketscreener.com
What's Going On With Lifeward Shares Thursday?Lifeward (NASDAQ:LFWD) - Benzinga
FDA Approval of ReWalk7 Sends Lifeward (LFWD) Stock Climbing - Stocks Telegraph
Lifeward announces FDA clearance for ReWalk 7 exoskeleton - TipRanks
Lifeward Receives FDA Clearance for ReWalk 7 Exoskeleton; Shares Jump -March 13, 2025 at 09:41 am EDT - Marketscreener.com
Lifeward gains FDA clearance for new ReWalk exoskeleton By Investing.com - Investing.com UK
FDA Issues Clearance for ReWalk 7 Exoskeleton - GlobeNewswire
Revolutionary ReWalk 7 Exoskeleton Gets FDA Green Light, Medicare Coverage Ready - StockTitan
Nasdaq Down Over 100 Points; US Producer Inflation Stalls In February - Benzinga
Lifeward stock holds Buy rating and $13 target from H.C. Wainwright - Investing.com Australia
Positive Outlook for Lifeward Driven by Strategic Partnerships and Market Expansion Initiatives - TipRanks
Lifeward stock holds Buy rating and $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Lifeward reports operating loss of USD 15.2M in Q4 2024 - Medical Buyer
Lifeward Ltd (LFWD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... - Yahoo Finance
Lifeward Ltd. Reports Strong 2024 Revenue Growth - TipRanks
Lifeward: Q4 Earnings Snapshot - The Washington Post
Lifeward earnings missed by $0.19, revenue fell short of estimates - Investing.com South Africa
Lifeward Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Lifeward Ltd Reports Q4 2024 Earnings: EPS of -$1.73 Misses Esti - GuruFocus.com
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Lifeward reports Q4 EPS ($1.73) vs (66c) last year - TipRanks
Lifeward Ltd. Reports Record Annual Revenue of $25.7 Million and Launches 2025 Sustainable Growth Plan - Nasdaq
Lifeward expects Q1 revenue to be the lowest of the year - TipRanks
Lifeward and CorLife Finalize Partnership to Expand Workers’ Compensation Access to ReWalk Exoskeleton - GlobeNewswire
Lifeward and MYOLYN expand contract for home therapy system By Investing.com - Investing.com Canada
Lifeward, MYOLYN expand partnership to enhance patient access to MyoCycle - TipRanks
Lifeward and MYOLYN expand contract for home therapy system - Investing.com India
Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use - The Manila Times
Lifeward Ltd. and MYOLYN Expand Partnership to Enhance Access to MyoCycle FES Therapy for Home Rehabilitation - Nasdaq
Lifeward and MYOLYN Expand Partnership to Enhance Patient - GlobeNewswire
Lifeward Secures Exclusive Rights to Transition MyoCycle Therapy Patients from Clinic to Home - StockTitan
Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025 - GlobeNewswire
1 Healthcare Stock to Own for Decades and 2 to Ignore - The Globe and Mail
Medical Tech Leader Lifeward Sets Date for 2024 Financial Results Reveal - StockTitan
Rehabilitation Robots Market Size Expected to Reach USD 1776.24 Mn by 2034 - GlobeNewswire Inc.
Lifeward Ltd expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lifeward CEO Larry Jasinski to step down - MSN
Lobbying Update: $15,000 of LIFEWARD (FORMERLY REWALK ROBOTICS INC.) lobbying was just disclosed - Nasdaq
Lifeward CEO Larry Jasinski to Retire - citybiz
Lifeward Ltd (LFWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
0.15%
자본화:
|
볼륨(24시간):